AstraZeneca plc Forecasted to Earn FY2022 Earnings of $3.15 Per Share (AZN)
AstraZeneca plc (NYSE:AZN) – Equities researchers at Leerink Swann issued their FY2022 earnings per share (EPS) estimates for AstraZeneca in a research note issued to investors on Thursday. Leerink Swann analyst S. Fernandez forecasts that the company will earn $3.15 per share for the year. Leerink Swann has a “Market Perform” rating and a $36.00 price target on the stock.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.32 earnings per share.
AstraZeneca (NYSE AZN) traded up $0.37 during trading hours on Friday, reaching $35.44. The company had a trading volume of 2,527,393 shares, compared to its average volume of 3,040,000. The stock has a market capitalization of $88,530.00, a price-to-earnings ratio of 25.31, a PEG ratio of 2.59 and a beta of 0.76. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. AstraZeneca has a 52-week low of $26.51 and a 52-week high of $35.92.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AZN. WFG Advisors LP boosted its stake in AstraZeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after acquiring an additional 984 shares in the last quarter. Valeo Financial Advisors LLC acquired a new position in AstraZeneca in the third quarter valued at $133,000. Quadrant Capital Group LLC boosted its stake in AstraZeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after acquiring an additional 846 shares in the last quarter. Wealthcare Advisory Partners LLC acquired a new position in AstraZeneca in the third quarter valued at $184,000. Finally, FTB Advisors Inc. boosted its stake in AstraZeneca by 3.2% in the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 14.75% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/19/astrazeneca-plc-forecasted-to-earn-fy2022-earnings-of-3-15-per-share-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.